ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 574

Do Extra-Articular Manifestations Influence Outcome in Ankylosing Spondylitis? a 12 Year Follow-up Study

Ivette Essers1,2, Sofia Ramiro3,4, Carmen Stolwijk1,2, Marc Blaauw5, Robert Landewé6,7, Désirée M. van der Heijde8, Filip van Den Bosch9, Maxime Dougados10 and Astrid van Tubergen2,11, 1School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 2Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, 4Rheumatology, Hospital Garcia de Orta, Almada, Portugal, 5Department of Internal Medicine, Catharina Hospital, Eindhoven, Netherlands, 6Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 7Rheumatology, Atrium Medical Center, Heerlen, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 9Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 10Rheumatology, Hopital Cochin, Descartes University, Paris, France, 11Maastricht University Medical Center, Maastricht, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), extraarticular manifestations and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Extra-articular manifestations (EAMs), such as acute anterior uveitis (AAU), inflammatory bowel disease (IBD), and psoriasis contribute to diagnosis, classification criteria, and choice of treatment in patients with ankylosing spondylitis (AS). Therefore, the aim of the present study is to assess whether the presence of EAMs is associated with more functional disability, worse quality of life (QoL), and more radiographic damage in patients with AS over time. 

Methods: Twelve-year follow-up data from all patients included in the Outcome in Ankylosing Spondylitis International Study (OASIS) were used. The presence of EAMs was extracted from medical charts by two independent extractors. Function was assessed by the Bath AS Functional Index (BASFI), and the physical component of the Short Form-36. QoL was assessed by the ASQoL, and EuroQoL. Radiographic damage was assessed by the modified Stoke AS Spinal Score. Time adjusted univariable and multivariable generalized estimating equations analyses were performed to assess whether prevalent and incident EAMs, respectively, were associated with functional disability, QoL, and radiographic damage over time. Patients with prevalent EAMs were excluded from the analysis involving incident EAMs. 

Results: 216 Patients were included (154 (71%) men, mean age 43.6 years (SD 12.7), mean symptom duration 20.5 years (SD 11.7), and mean follow-up 8.3 years (SD 4.1)). At baseline, 39 (18%) patients had AAU, 15 (7%) IBD, and 9 (4%) psoriasis (prevalent cases). During follow-up, 19 patients developed AAU, 9 IBD, and 5 psoriasis (incident cases). Psoriasis was excluded from further analyses, because of a low prevalence and incidence in this cohort. Prevalent AAU was univariably associated with more radiographic damage (B=7.19, 95%-Confidence Interval [CI] 0.19 to 14.19, p=0.04) over time, but in a multivariable model this association was no longer significant (B=1.22, 95%-CI -3.81 to 6.26, p=0.64). Prevalent IBD was not associated with any of the clinical outcomes over time. Incident AAU was also not associated with clinical outcomes over time. Incident IBD, however, showed a trend towards worse function (BASFI) over time in a univariable model (B=1.86, 95%-CI -0.08 to 3.80, p=0.06), and also in a multivariable model (B=1.40, 95%-CI -0.04 to 2.84, p=0.06).

Conclusion: Prevalent AAU and IBD at baseline were not associated with a worse course of QoL, function, or radiographic damage over time. However, patients with new-onset IBD tended to have more functional disability over time in comparison with patients who do not develop IBD.


Disclosure:

I. Essers,
None;

S. Ramiro,
None;

C. Stolwijk,
None;

M. Blaauw,
None;

R. Landewé,

AbbVie, Amgen, BMS, Centocor, GSK, Merck, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth,

5,

Rheumatology Consultancy bv,

4;

D. M. van der Heijde,

AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Vertex,

2,

AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Vertex,

5,

Imaging Rheumatology BV,

9;

F. van Den Bosch,
None;

M. Dougados,

Pfizer Inc; Abbvie;Novartis,Sanofi,Lilly,UCB,

2,

Pfizer Inc; Abbvie;Novartis,Sanofi,Lilly,UCB,

5;

A. van Tubergen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-extra-articular-manifestations-influence-outcome-in-ankylosing-spondylitis-a-12-year-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology